Toxic epidermal necrolysis and Stevens-Johnson syndrome: New issues in classification and therapy;Necrólisis epidérmica tóxica y síndrome de Stevens-Johnson: Clasificación y actualidad terapéutica

Actas Dermo-Sifiliograficas

Volumn 91, Issue 12, 2000, Pages 541-551

  García Doval, Ignacio ^b   Roujeau, Jean Claude ^a   Cruces Prado, Manuel J ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b HOSPITAL MONTECELO   (Spain)

^c NONE

Author keywords

Stevens Johnson syndrome; Therapy; Toxic epydermal necrolysis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; PENTOXIFYLLINE;

APOPTOSIS; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; IMMUNE RESPONSE; PLASMAPHERESIS; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 0004180784     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Avakian R, Flowers FP, Araújo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25:69-79.
2. Roujeau J-C, Chosidow O, Saiag P, Guillaume J-C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039-58.
3. a ed. Oxford: Blackwell Scientific Publications; 1992. p. 18.34-18.38.
4. a ed. Nueva York: McGraw-Hill; 1993. p. 585-600.
5. Böttiger LE, Strandberg I, Westernholm B. Drug induced febrile mucocutaneous syndrome. Acta Med Scand 1975; 198:226-33.
6. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2 and 3: study of sixty cases. J Am Acad Dermatol 1985;13:229-33.
7. Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol 1990;122:837-8.
8. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-61.
9. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophtalmia. Report of two cases in children. Am J Dis Child 1922;24:526-33.
10. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnosis, criteria, and causes. J Am Acad Dermatol 1983;8:763-75.
11. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. A clinical clasification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6.
12. Assier H, Bastuji-Garin S, Revuz J, Roujeau J-C. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995;131:539-43.
13. Côte B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau J-C. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995;131:1268-72.
14. Roujeau J-C, Kelly JP, Naldi L, y cols. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
15. Villada G, Roujeau J-C, Clérici T, Bourgault I, Revuz J. Immunopathology of toxic epidermal necrolysis. Arch Dermatol 1992;128:50-3.
16. Correia O, Delgado L, Ramos JP, Resende C, Fleming Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993;129:466-8.
17. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Pierrard GE. Macrophages and tumor necrosis factor in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-8.
18. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155:462-72.
19. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4.
20. Heng MCY, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis, clinical and pathophysiologic aspects. J Am Acad Dermatol 1991;25:778-86.
21. Friedman PS, Strickland I, Pirmohamed M, Park BK. Investigations of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
22. Peñas PF, Ríos L, Buezo GF, García-Díez A. Apoptosis. Revision de mecanismos moleculares e implicaciones en dermatología. Actas Dermosifiliogr 1998;89:3-13.
23. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3.
24. García Doval I, Peteiro C, Toribio J. Insuficiencia cutánea aguda: fisiopatología y actitud terapéutica. Piel 1995;10: 187-90.
25. Roujeau J-C, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994;331:1272-85.
26. Roujeau JC. Treatment of SJS and TEN. En: Kauppinen K, Alanko K, Hannuksela M, Maibach H, eds. Skin reactions to drugs. Boca Ratón: CRC Press; 1998. p. 141.
27. Roudier C, Caumes E, Rogeaux O, Bricaire F, Gentilini M. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Arch Dermatol 1994;130:1383-6.
28. Drake LA, Dinehart SM, Farmer ER, y cols. Guidelines of care for cutaneous adverse drug reactions. J Am Acad Dermatol 1996;35:458-61.
29. García Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epydermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of the causative drug decrease the risk of death? Arch Dermatol 2000;136:323-7.
30. Revuz J, Penso D, Roujeau J-C, y cols. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
31. Monafo WW. Current concepts: initial management of bums. N Engl J Med 1996;335:1581-6.
32. McIvor RA, Zaidi J, Peters WJ, Hyland RH. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996;17:237-40.
33. Arévalo JM, Lorente JA. Tratamiento de la necrólisis epidérmica tóxica. Med Clín (Barc) 1998;111:27-31.
34. Arévalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 1999;20:406-10.
35. Saiag P, Roujeau JC. Intérêts et limites du lit fluidisé en dermatologie. Ann Dermatol Venereol 1993;120:477-80.
36. Tegelberg-Stassen MJ, Van Vloten WA, Baart de la Faille H. Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. Dermatologica 1990;180:124-9.
37. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993;128:357.
38. Patterson R, Miller M, Kaplan M, y cols. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994;76:27-34.
39. Garabiol B, Touraine R. Syndrome de Lyell de l'adulte éléments de pronostic et déductions thérapeutiques. Etude de 27 cas. Ann Med Intern (Paris) 1976;127:670-2.
40. Kim PS, Goldfarb IW, Gaisford JC, y cols. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil 1983;4:91-100.
41. Halebian PH, Corder VJ, Madden MR, y cols. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.
42. Kelemen JJ, Cioffi WG, McManus WF, Mason AD, Pruitt BA. Burn center care for patients with toxic epidermal necro-lysis. J Am Coll Surg 1995;180:273-8.
43. Herndon DN. Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg. 1995; 180:340-2.
44. Rzany B, Schmitt H, Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol (Stockh) 1991;71:171-2.
45. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-72.
46. Hertl M, Bohlen H, Merk HF. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1993;28:511.
47. Frangogiannis NC, Boridy I, Mazhar M, Mathews R, Gangopadhyay S, Cate T. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996;89:1001-3.
48. Valks R, Ríos Buceta L, Porras JI, Buezo GF, Dauden E. Necrólisis epidérmica tóxica en áreas fotoexpuestas tras ingesta de piroxicam. Respuesta a la ciclofosfamida. Actas Dermosifiliogr 1995;86:437-41.
49. Pacquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999;198:198-202.
50. Renfro L, Grant-Kels JM, Daman LA. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989;28:441-4.
51. Hewitt J, Ormerod AD.Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol 1992;17:264-5.
52. Zaki I, Patel S, Reed R, Dalziel KL. Toxic epidermal necrolysis associated with severe hypocalcemia and treated with cyclosporin. Br J Dermatol 1995;133:337-8.
53. Sullivan JR, Watson A, Lamotrigine induced toxic epydermal necrolysis treated with intravenous cyclosporine: a discussion of pathogenesis and immunosuppresive management. Australas J Dermatol 1996;37:208-12.
54. Jarret P, Rademaker M, Havill J, Pullon H. Toxic epydermal necrolysis treated with cyclosporin and granulocyte colony simulating factor. Clin Exp Dermatol 1997;22:146-7.
55. Palomo Arellano A, Rodríguez Gómez J, Guerrero Vega, E, Arbol Linde F, Marcos Sánchez F. Necrólisis epidérmica tóxica inducida por lamotrigina. Tratamiento con ciclosporina. Actas Dermosifiliogr 1999;90:612-5.
56. Gérard A, Schooneman F, Roche G, y cols. Lyell's syndrome: treatment by plasma exchange. Plasma Ther Transfus Technol 1984;5:259-60.
57. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-9.
58. Sakellariou G, Koukoudis P, Karpouzas J, y cols. Plasma exchange treatment in drug-induced toxic epidermal necrolysis. Int J Artif Organs 1991;14:634-8.
59. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36:218-21.
60. Merle C, Blanc D, Flesch M, Carbillet JP, Miguet JP, Gillet M. Tableu de nécrolyse épidermique après allogreffe hépatique, discussion étiologique. Ann Dermatol Venereol 1990; 117:635-9.
61. Redondo P, Ruiz de Erenchum F, Iglesias ME, Monodero P, Quintanilla E. Toxic epidermal necrolysis, treatment with pentoxifyllin. Br J Dermatol 1994;130:688-9.
62. Wolkenstein P, Latarjet J, Roujeau JC, y cols. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
63. Armato GM, Travia A, Ziino O. Impiego delle immunoglobuline endovenosa ad alto dosi (IGEV) in un caso di sindrome di Stevens-Johnson. Med Sur Ped 1992;14:555-6.
64. Moudgil A, Porat S, Brunnel P, Jordan SC. Treatment of Stevens-Johnson syndrome with pooled human intravenous immune globulin. Clin Pediatrics 1995;34: 47-51.
65. Ruocco V, Bimonte D, Luongo C, Florio M. Hyperbaric oxygen treatment of toxic epidermal necrolysis. Cutis 1986; 38:267-71.
66. Meneux E, Paniel BJ, Pouget F, Revuz J, Roujeau JC, Wolkenstein P. Vulvovaginal sequelae in toxic epidermal necrolysis. J Reprod Med 1997;42:153-6.